In clinical trials, there is a critical advancement in the usage of targeted NIR imaging agents that bind specifically to the EGFRs for head and neck tumor (NCT01987375), folate receptor for ovarian (NCT02317705), and PSMA for prostate cancer (NCT02048150) respectively. The gene discussed is FOLH1; the disease is head and neck neoplasm.